NetworkNewsBreaks – Cybin Inc. (NYSE American: C
Post# of 341
(Total Views: 170)
Posted On: 03/21/2022 3:36:22 PM
NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Planning Pilot Study of CYB004, Pursuing Multiple Opportunities to Secure, Support Patent Position for R&D
Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, recently received its first official issued patent. The U.S. Patent and Trademark Office (“USPTO”) has granted patent 11,242,318 to Cybin’s proprietary CYB004, the company’s lead investigational proprietary DMT compound. According to Cybin CEO Doug Drysdale, the patent adds strong protection to the company’s growing intellectual property portfolio of psychedelic-based compounds, supporting and protecting the investments it is making in its CYB004 program. “Under the patent, allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT; the patent also covers composition of matter and protects the CYB004 drug substance as a putative new chemical entity until 2041,” a recent article reads. “Looking forward, the company is planning a pilot study of CYB004; Cybin intends to submit a clinical trial application for the study in coming weeks with expectations to begin the study in Q3 of 2022. In addition, Cybin will follow up on multiple opportunities to secure and support its patent position for research and development evaluating deuterated tryptamines for future psychedelic-based treatments for mental illnesses.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, recently received its first official issued patent. The U.S. Patent and Trademark Office (“USPTO”) has granted patent 11,242,318 to Cybin’s proprietary CYB004, the company’s lead investigational proprietary DMT compound. According to Cybin CEO Doug Drysdale, the patent adds strong protection to the company’s growing intellectual property portfolio of psychedelic-based compounds, supporting and protecting the investments it is making in its CYB004 program. “Under the patent, allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT; the patent also covers composition of matter and protects the CYB004 drug substance as a putative new chemical entity until 2041,” a recent article reads. “Looking forward, the company is planning a pilot study of CYB004; Cybin intends to submit a clinical trial application for the study in coming weeks with expectations to begin the study in Q3 of 2022. In addition, Cybin will follow up on multiple opportunities to secure and support its patent position for research and development evaluating deuterated tryptamines for future psychedelic-based treatments for mental illnesses.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Cybin Inc (CYBN) Stock Research Links
Scroll down for more posts ▼